Vidofludimus calcium

N/A

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NameVidofludimus calcium
Drug Alias NameIM-90838IMU-838
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBosnia and HerzegovinaArmenia +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator Companies4sc Ag
China Registration ClassN/A

Develop Information

Active CompaniesImmunic IncImmunic Ag4sc Ag
Inactive CompaniesArizona State University
Active IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Inactive IndicationsColitis, UlcerativeCholangitis, Sclerosing

Other Information

ATC CodeN/A
Related LinksN/A